Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19

Dániel Szili, Marcell Cserhalmi, Zsuzsanna Bankó, György Nagy, David E. Szymkowski, Gabriella Saŕmay

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The Fc receptor (FcγRIIb) inhibits B cell responses when coengaged with B cell receptor (BCR), and has become a target for new autoimmune disease therapeutics. For example, BCR and FcγRIIb coengagement via the Fc-engineered anti-CD19 XmAb5871 suppresses humoral immune responses. We now assess effects of XmAb5871 on other activation pathways, including the pathogen-associated molecular pattern receptor, TLR9. Since TLR9 signaling is implicated in autoimmune diseases, we asked if XmAb5871 could inhibit TLR9 costimulation. We show that XmAb5871 decreases ERK and AKT activation, cell proliferation, cytokine, and IgG production induced by BCR and/or TLR9 signals. XmAb5871 also inhibited differentiation of citrullinated peptide-specific plasma cells from rheumatoid arthritis patients. XmAb5871 may therefore have potential to suppress pathogenic B cells in autoimmune diseases.

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalmAbs
Volume6
Issue number4
DOIs
Publication statusPublished - Jan 1 2014

Keywords

  • Antibody therapy
  • Autoimmune
  • B cell
  • Fc-engineered
  • Humanized antibody
  • Rheumatoid arthritis
  • Signaling
  • TLR

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19'. Together they form a unique fingerprint.

  • Cite this